A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/506 (2006.01) A61P 9/10 (2006.01)
Patent
CA 2361600
The use of moxonidine and its physiologically compatible acid addition salts for the manufacture of pharmaceutical preparations for the treatment of myocardial damage secondary to myocardial infarction is described. Pharmaceutical preparations containing moxonidine and its physiologically compatible acid addition salts are suitable for use in acute myocardial infarction and/or postmyocardial infarction management. In addition to a beneficial influence, promoting recovery and/or rehabilitation, on the myocardial status following myocardial infarction, moxonidine and its physiologically compatible acid addition salts, especially when used in the management of postmyocardial infarction patients in the chronic stage, also show a preventive effect against the progression of heart failure after myocardial infarction.
Utilisation de moxonidine et de ses sels d'addition d'acide physiologiquement compatibles pour la préparation de compositions pharmaceutiques destinées au traitement des lésions du myocarde consécutives à un infarctus. Des préparations pharmaceutiques contenant de la moxonidine ou ses sels d'addition d'acide physiologiquement compatibles sont adaptées pour être utilisées dans le cadre du traitement de l'infarctus du myocarde au stade aigu et/ou du traitement post-infarctus du myocarde.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Solvay Pharmaceuticals Gmbh
LandOfFree
Use of moxonidine for postmyocardial infarction treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of moxonidine for postmyocardial infarction treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of moxonidine for postmyocardial infarction treatment will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2039577